Panacea backs Tactiva in $35M series A

Cancer immunotherapy company Tactiva Therapeutics Inc. (Buffalo, N.Y.) announced Dec. 3 it raised $18 million in the first tranche of a $35 million series A round led by Chinese VC firm Panacea Ventures. VI Ventures and EFung Capital also participated.

Tactiva is developing adoptive T cell therapies using T cell receptors for both CD4+ and CD8+ cells to treat various cancer indications. The funding is intended to move its lead candidates into clinical development in 2019, including a multiple myeloma (MM) trial and a basket trial in solid tumors...